Categories: LATEST NEWS

GE Healthcare to commercialize Rapiscan® outside the US, Canada & Mexico for increased access to heart exams

GE Healthcare’s Life Sciences business announced today that it has acquired Rapidscan Pharma Solutions Inc., which has the exclusive rights to produce and sell the pharmacological stress agent Rapiscan® (regadenoson) in territories outside the USA, Canada and Mexico. GE Healthcare’s strong industry presence and existing customer and supply chain network will help bring improved access to Rapiscan, offering an alternative screening method for patients who are unable to undergo traditional cardiac stress imaging procedures.

Rapiscan® is a European Medicines Agency (EMA) approved selective coronary vasodilator, used as a pharmacological stress agent for radionuclide myocardial perfusion imaging (MPI) in adult patients. It is used in the diagnosis of coronary artery disease (CAD), the most common type of cardiovascular disease, accounting for over 680,000 deaths in Europe alone[1] .

While MPIs are most commonly performed after a patient has exercised, some patients at risk of CAD cannot exercise due to various conditions such as asthma and chronic obstructive pulmonary disease. Rapiscan reduces the risks[2] of MPI tests for these patients by stimulating a patient’s heart to bring on the effects of exercise.

Emmanuel Ligner, General Manager of Core Imaging for GE Healthcare’s Life Sciences business, said: “Rapiscan is a perfect fit for our current cardiac imaging agent portfolio, as it enables access to a critical diagnostic test to a large, under-served population of patients at risk of coronary artery disease. As Rapiscan is a market leader in Germany and Austria[3] but largely unavailable in many other regions, we will use GE Healthcare’s industry scale to drive improved access to this diagnostic tool for patients worldwide.”

GE Healthcare already distributes Rapiscan in the UK and Germany and will maintain existing supplier and distributor networks created by Rapidscan Pharma Solutions to expand its global reach. Its commercial rights will complement Astellas’ commercial distribution of regadenoson in the US, Canada, and Mexico.

Liat

Recent Posts

QuamCore Emerges from Stealth with $9 Million in Seed Funding to Build World’s First Scalable 1 million Qubit Quantum Computer

Breakthrough in superconducting digital logic removes quantum scaling barriers, paving the way for large-scale quantum…

2 days ago

Qualcomm to Bolster AI and IoT Capabilities with Edge Impulse Acquisition

Highlights:  Acquisition complements strategic approach to IoT transformation, enhances developer enablement and expands leadership in…

5 days ago

Tower Semiconductor and Innolight Expand their Collaboration and Ramp Volume of Next-Generation SiPho Solutions for AI and Data Centers

New Technology Halves Laser Requirements for Streamlined, High-Volume Optical Module Production to Meet Growing AI…

5 days ago

Lenovo Just Launched the World’s First Laptop with an Under-Display Camera: Here’s How They Did It

Lenovo has redefined laptop innovation with the introduction of the Yoga Slim 9i, the world’s…

1 week ago

Power Supplies 10 to 50W industrial power supply series expanded with new mounting and protection options for increased system flexibility

TDK Corporation (TSE 6762) announces the introduction of multiple option configurations for the TDK-Lambda brand…

1 week ago

Nordic Semiconductor collaborates with Deutsche Telekom to make everything cellular connected

Introducing MECC: A seamless, scalable solution to unlock global IoT connectivity using nRF9151 module Nordic…

1 week ago